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Type I interferons might form the link between Toll-like receptor
(TLR) 3/7 and TLR4-mediated synovial inflammation in
rheumatoid arthritis (RA)
Abstract
BACKGROUND: Rheumatoid arthritis (RA) has been associated with an increased risk of infections,
but the underlying pathways have not yet been identified. Toll-like receptors (TLR) probably play a role
in synovial inflammation and may also contribute to the understanding of the role of infections in RA.
OBJECTIVES: To investigate if the synovial expression of TLR3 and TLR7 in RA correlates with that
of inflammatory cytokines, and to assess whether this has functional consequences for local cytokine
production and to study potential links between the TLR3/7 axis and TLR4 in RA synovium.
METHODS: Immunohistochemistry was used to study the expression of TLR3, TLR7, interferon alpha
(IFNalpha), tumour necrosis factor alpha (TNFalpha) and interleukins IL1beta, IL12, IL17 and IL18 in
RA synovium obtained by arthroscopy from 34 patients with RA. Monocytes, monocyte-derived
dendritic cells (MoDCs) and RA synovial fibroblasts were stimulated via TLR3 (poly-IC) and TLR7
(loxorubin), after which IL1beta, IL6 and TNFalpha were measured by Luminex bead array technology.
Following preincubation with IFNalpha, IL1beta and IL18, TLR3 and TLR7 mRNA expression was
assessed using real-time PCR. Cytokine production after preincubation with IFNalpha and subsequent
TLR stimulation was measured. RESULTS: Synovial TLR3/7 expression was co-expressed with
IFNalpha, IL1beta and IL18, but not with TNFalpha, IL12 and IL17. Stimulation of TLR3/TLR7 on
monocytes, MoDCs or synovial fibroblasts led to secretion of type I IFN but no biologically active
IL1beta or IL18 could be detected. Type I IFNalpha increased TLR3/7 mRNA expression whereas
IL1beta and IL18 did not. In spite of the fact that the mRNA level of TLR4 remained unchanged,
IFNalpha enhanced the response to TLR4 agonists, a phenomenon that was clearly more marked in
patients with RA. CONCLUSION: Type I interferons are highly co-expressed with TLR3/TLR7 in RA
synovium. They enhance TLR3/TLR7-mediated cytokine production and also TLR4-mediated
responses.
Type I interferons might form the link between Toll-like receptor (TLR) 3/7 and 
TLR4 mediated synovial inflammation in rheumatoid arthritis (RA).  
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Abstract 
 
Rationale: Toll like receptors (TLR) are likely to play a role in synovial inflammation. 
Rheumatoid arthritis had been associated with infections but the underlying pathways 
have never been identified. A hypothetical link between various TLR pathways would 
contribute to our understanding on the role of infections in RA.  
 
Objective: To investigate if the increased synovial expression of Toll-like receptor 
(TLR) 3 and TLR7 in RA correlates with inflammatory cytokines, whether this has 
functional consequences for cytokine production and to study a potential link 
between TLR3/7 axis and TLR4 in RA synovium.  
 
Methods: Immunohistochemistry was used to study the expression of TLR3, TLR7, 
IFN, TNF, IL-1, IL-12, IL-17 and IL-18 in RA synovium from 34 RA patients 
obtained via arthroscopy. Monocytes, monocyte-derived dendritic cells and RA 
synovial fibroblasts were stimulated via TLR3 (Poly-IC) and TLR7 (loxorubin) after 
which IL-1, IL-6 and TNF was measured by Luminex bead array technology. Upon 
pre-incubation with IFN, IL-1 and IL-18 TLR3 and TLR7 mRNA expression upon 
was assessed using real-time PCR. Cytokine production after pre-incubation with 
IFN and subsequent TLR stimulation was measured.  
 
Results: Synovial TLR3/7 expression was co-expressed with IFN, IL-1 and IL-18, 
but not with TNF, IL-12 and IL-17. Stimulation of TLR3/TLR7 on monocytes, MoDC 
or synovial fibroblasts led to secretion of type I IFN whereas no biologically active IL-
1 or IL-18 could be detected. Type I IFN was able to increase TLR3/7 mRNA 
expression whereas IL-1 and IL-18 was not. Strikingly, despite an unchanged 
mRNA level of TLR4, IFN led to an augmented response to TLR4 agonists, a 
phenomenon that was clearly enhanced in RA patients.  
 
Conclusion: Here we demonstrate that the type I interferons are highly co-
expressed with TLR3/TLR7 in RA synovium. Furthermore, we provide clear evidence 
for the functional role of type I interferons in enhancing not only TLR3/TLR7 mediated 
cytokine production but also augmenting TLR4 mediated responses.  
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Introduction 
Rheumatoid arthritis (RA) is a systemic autoimmune disease, which is characterized 
by chronic inflammation of the synovial joints. Although the cause of RA is still 
unidentified, a role both for genetic and environmental factors has been advocated 
repeatedly throughout time. As environmental factors, the encounter of bacteria 
and/or viruses by the host was suggested to trigger autoimmunity. Indeed, evidence 
for the presence of at least some viruses including Cytomegalovirus (1, 2), Epstein-
Barr virus (3) and Parvovirus B19 (4) was demonstrated. In line with these 
observations, it was demonstrated that dsRNA, which is a common feature of 
viruses, exerts clear arthrogenic properties (5), further substantiated the potential role 
of viruses in RA. Although recent studies demonstrated a type I interferon (IFN) 
signature in the RA synovium the underlying pathways that explains the role for type I 
IFN remains elusive (6). 
 
Accumulating evidence suggests a role for the Toll-like receptor (TLR) family in the 
type I IFN mediated response. TLR belong to the family of pattern-recognition 
receptors (PRR), which were first identified to recognize microbial components, 
known as pathogen-associated patterns (PAMPs). TLR are constitutively expressed 
by numerous immune cells and designed to detect and eliminate invading pathogens 
by activation of both innate as well as adaptive immune responses. TLR3 and 7 
serve as receptors for double stranded and single stranded (viral) RNA respectively 
and TLR9 serves as a receptor for unmethylated CpG motifs in (viral / bacterial) 
DNA. Therefore they have a key role in antiviral immunity by inducing type I IFN 
production (7-9). In contrast, TLR2 and TLR4 elicit immune responses upon binding 
of antigens from bacterial origin and host-derived molecules (so-called endogenous 
ligands or alarmins) ending up in the production inflammatory mediators including 
TNF- and IL-1 (10-13). The increased expression of various TLR subtypes in the 
synovial tissue of rheumatoid arthritis patients further substantiates the potential role 
of TLR in RA. More recently, the role of TLR in the inflammatory cascade of arthritis 
was highlighted in experimental models of arthritis (14, 15). Although TLR and its 
ligands are abundantly present in the synovial compartment of RA patients, it is hard 
to conceive that any trigger of a single TLR subtype would be sufficient to convert 
tolerance to immunity. If such, then autoimmunity should regularly follow from 
infections. It is therefore more likely that more then one TLR ligand is needed for the 
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initiation of a chronic and persisting inflammatory response as seen during RA. 
Accordingly, recent research suggested that simultaneous or sequential triggering of 
different pathways pathways is perhaps the event that sets off autoimmunity (16). In 
this light, it is tantalizing to speculate that simultaneous triggering of different TLR 
pathways might initiate a series of events that forms the basis of the breakthrough of 
tolerance.  Previous evidence from our group demonstrated a synergistic effect with 
regard to cytokine production when stimulation of two (or more) TLR subtypes was 
achieved on dendritic cells. Here we sought evidence for a potential link between 
TLR2/4 and TLR3/7 pathways in RA inflammation. 
 
Here we demonstrate that IL-1 and IL-18, IFN (the classic type I interferon) are co-
expressed with TLR3/7 in RA synovium. In addition, we provide evidence that type I 
IFN increase the expression of TLR3 and TLR7, but not TLR4, leading to an 
increased production of cytokines upon TLR3/TLR7 specific triggering. Interestingly, 
type I IFN also induced a clear augmentation of TLR4 mediated production of pro-
inflammatory mediators including IL-6, IL-1 and TNF, which was clearly more 
potent in RA. These data illustrate that TLR3/TLR7 stimulation indirectly lowers the 
threshold for TLR4 mediated immune activation setting the stage for the vicious circle 
of inflammation as observed in RA. Altogether, these observations underscore the 
potential role of viruses in RA and provide rationale for interference with TLR 
signalling in RA.  
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Methods 
Patients / study population 
For immunohistochemistry, synovial biopsies from RA patients (n=34) were obtained, 
using small needle arthroscopy, from the medial and lateral supra-patellar pouch on 
each occasion. The local Medical Ethics Committee approved the study protocol. For 
in vitro experiments, heparinized venous blood was collected from 10 RA patients 
and 11 healthy volunteers. Patients were attending the department of Rheumatology 
of the Radboud University Nijmegen Medical Centre, fulfilled the American College of 
Rheumatology criteria for and they all gave their informed consent (17). Patients 
using high dose prednisolone (>10mg/day) or anti-cytokine therapies (anti-TNF 
and/or IL-1Ra) were excluded from this study. The local Medical Ethics Committee 
approved the study protocol. 
 
Immunohistochemical staining of synovial biopsies. 
Tissue samples were immediately fixed with 4% formaldehyde and embedded in 
paraffin. Staining of IL-1, IL-12, IL-17, IL-18 and TNF was performed as described 
previously (18). For TLR3, TLR7 and IFN staining, sections were incubated for 60 
minutes with antibodies against human TLR3 (T-17), human TLR7 (V-20) or IFN 
(FL-198), which were all obtained from Santa Cruz, California, USA. After this, 
endogenous peroxidase was blocked with 3% H2O2 in methanol for 15 minutes and 
subsequently the appropriate biotinylated secondary antibody (mouse anti-goat: 
Jackson ImmunoResearch, West Grove, PA, USA / swine anti-rabbit: 
DakoCytomation, Glostrup, Denmark) was incubated for 30 minutes. For TLR3 and 
TLR7 staining, Vectastain ABC (Vector Laboratories, Burlingame, CA, USA) reagent 
was incubated for 30 minutes, developed with DAB (Sigma, St. Louis, MO, USA), and 
counterstained with hematoxilin for 30 seconds. For IFN staining, sections were 
incubated with streptavidin-PO (DakoCytomation, Glostrup, Denmark), developed 
with DAB (Sigma, St. Louis, MO, USA), and counterstained with hematoxilin for 30 
seconds. Staining was semi quantitatively scored on a 5-point scale (scores 0-4) at 
200x magnification; a score of 0 represented no or minimal staining, score 1 stands 
for 10%-20% positive cells, 2 for 30%-40%, 3 for 50%-60%, and a score of 4 
represented staining of a more that 60% of the cells.  
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Isolation and culturing of monocytes and monocyte-derived DC (MoDC). 
PBMC were isolated from heparinized venous blood using density gradient 
centrifugation over Ficoll-Paque (Amersham Biosciences, Roosendaal, The 
Netherlands). Low-density cells were collected and washed with citrated PBS 5% 
FCS. For monocytes, CD14+ cell fraction was isolated using MACS cell separation, 
according to the manufacturer’s instructions. Briefly, PBMC were incubated with anti-
human CD14 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) for 30 
minutes, subsequently cells were washed and CD14+ fraction was separated from 
the CD14- fraction over a MACS MS separation column (Miltenyi Biotec, Bergisch 
Gladbach, Germany). CD14+ cell fraction was eluted from the column, washed again 
and resuspended in a concentration of 0,5x106 cells/ml in RPMI 1640 Dutch 
Modification (Invitrogen Corporation, Carlsbad, CA, USA), supplemented with 10% 
FCS, plated in 6-well plates and O/N cultured at 37C and 5% CO2.  
For monocyte-derived dendritic cells, PBMC were allowed to adhere for 1 hour at 
37C in RPMI-1640 Dutch Modification (Invitrogen Corporation, Carlsbad, CA, USA 
supplemented with 2% human serum (PAA Laboratories, Pasching, Austria) in 25cm2 
cell culture flasks (Corning Incorporated, NY, USA). Adherent monocytes were 
cultured in RPMI-1640 Dutch modification supplemented with 10% fetal calf serum 
(FCS) and antibiotic-antimycotic (Life Technologies) in the presence of IL-4 (500 
U/ml, Schering-Plough, Amstelveen, The Netherlands) and GM-CSF (800 U/ml, 
Schering-Plough, Amstelveen, The Netherlands) for 6 days. Fresh culture medium 
with the same supplements was added at day 3 where after immature DC were 
harvested at day 6. Immature DC were resuspended in fresh cytokine-containing 
culture medium, transferred to 6-well culture plates (Corning Incorporated, NY, USA) 
in a concentration of 0,5106 cells/ml and cultured for 16 hours at 37C and 5% CO2. 
 
Isolation and culturing of RA synovial fibroblasts. 
Immediately after surgery, the synovial tissue was minced and digested with Dispase 
at 37°C for 60 minutes. After washing, the cells were grown in Dulbecco's minimum 
essential medium (Gibco Invitrogen, Basel, Switzerland) supplemented with 10% 
FCS, 50 IU/ml penicillin/streptomycin, 2 mM L-glutamine, 10 mM HEPES, and 0.2% 
Fungizone (all from Gibco Invitrogen). Cell cultures were maintained at 37°C in a 
humidified incubator in an atmosphere of 5% CO2. For the experiments, cultured 
 6
synovial fibroblasts, between passages 4 and 8, were grown in 12-well culture plates 
(6 × 104 RASF/well) and cultured at for 16 hours 37C and 5% CO2. 
 
Stimulation of monocytes, MoDC and RA synovial fibroblasts. 
To study TLR mRNA expression upon cytokine stimulation, monocytes (which 
express TLR7), monocyte-derived DC and RASF (which both express TLR3) were, 
after 16 hours resting period, stimulated for 8 hours with TNF, IL-1, IFN, IL-12, IL-
17, IL-18 (all R&D systems, Minneapolis, MN, USA). Subsequently, culture 
supernatants were removed and 1ml TRIzol reagent (Sigma St. Louis, MO, USA) 
was added to the cells and stored at –20C until RNA isolation was performed.  
To study functional up regulation of TLR, monocytes, monocyte-derived DC and 
RASF were, after an 16 hours resting period, stimulated IFN with (R&D systems, 
Minneapolis, MN, USA) for 24 hours and subsequently stimulated with the TLR3 and 
TLR7 agonists poly(I:C) and loxoribin respectively (both Invivogen, San Diego, USA) 
or medium. After another 24 hours, culture supernatants were collected and stored at 
-20C until cytokine measurement was performed. In addition, to investigate the role 
of type I IFN various cell types were pre-incubated with 100 U/ml IFN for 16 hrs. 
  
RNA isolation and real-time PCR. 
Total RNA was extracted in 1ml of TRIzol reagent (Sigma St. Louis, MO, USA), an 
improved single-step RNA isolation method based on the method described by 
Chomczynski et al. (19). Quantitative real-time PCR was performed using the 
ABI/Prism 7000 sequence detection system (Applied Biosystems, Foster City, CA). 
PCR conditions were as followed: 2 min at 50°C and 10 min at 95°C followed by 40 
cycles of 15 s at 95°C and 1 min at 60°C, with data collection in the last 30 seconds. 
All PCR were performed with SYBR Green Master mix (Applied Biosystems), 10 ng 
cDNA, and primer concentration of 300 nmol/L in a total volume of 25 µl. 
Quantification of the PCR signals was performed by comparing the cycle threshold 
value (Ct) of the gene of interest of each sample with the Ct values of the reference 
gene GAPDH. Primers sequences for gene expression analysis for hGAPDH, hTLR3, 
hTLR7 and IL-1 are depicted in Table I.     
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Measurement of cytokines in culture supernatant 
TNF, IL-1, IL-6 and IL-10, IL-12p70 levels were measured in the supernatant of the 
cell cultures, using commercially available kits (Bio-Rad Laboratories, Hercules, 
USA) according to the manufacturer’s instructions (20). Cytokine levels were 
measured and analyzed with the Bio-Plex system (Bio-Rad Laboratories). Data 
analysis was done with Bio-Plex Manager software (Bio-Rad Laboratories).  
 
Statistical analysis 
Correlations of the expression of TLR and cytokines in human synovial biopsies were 
calculated using the Pearson Correlation test. Differences in mRNA expression and 
cytokine production, upon cell stimulation with cytokines and TLR agonists, were 
calculated using Mann-Whitney U test. P values were two sided and the level of 
significance was set at P<0,05. 
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Results 
In RA synovium TLR3/7 are co-expressed with IL-1 and IL-18, and IFN 
Synovial biopsies from 24 active RA patients were used to detect TLR3, TLR7 and 
IFN expression (18). TLR3/7 was associated with the expression levels of IFN, IL-
1 and IL-18 but not with IL-12, IL-17 and TNF. Not unanticipated, IFN was clearly 
co-expressed with TLR3 and TLR7 in the lining as well as the sublining from synovial 
biopsies (Table 2). Moreover, both IL-1 and IL-18 were associated with the 
expression of TLR in the lining although these correlations were weaker than that 
observed between TLR and type I IFN. In contrast, nor IL1 or IL-18 was associated 
with either TLR3 or TLR7 expression in the sublining.  TNF, IL-12, or IL-17 were not 
correlated with the TLR expression levels in RA synovium. 
 
TLR3/7 mediated stimulation of monocytes, dendritic cells or synovial fibroblasts 
could not explain its co-expression with IL-1/IL-18. 
Since we found co-expression between TLR3/7 and IFN, IL-1 and IL-18, we further 
investigated the functional relation between these mediators and TLR3/7. It is 
generally accepted that stimulation of TLR3/7 leads to the production of type I IFN. In 
line with this, we found that TLR3/7 stimulation resulted in clearly enhanced IFN 
mRNA and IFN protein levels (data not shown). In order to investigate the potential 
relation between TLR3/7 and IL-1 we stimulated TLR3-expressing monocyte-
derived DC and synovial fibroblasts with poly(IC) and TLR7-expressing monocytes 
with loxoribine. All cell types investigated showed markedly increased expression of 
IL-1 mRNA upon stimulation of either TLR3 or TLR7, however IL-1 protein could 
not be detected (data not shown). The stimulation of monocytes, monocyte-derived 
DC or synovial fibroblasts with TLR3/7 did not lead to the secretion of IL-18 proteins.  
 
TLR3/7 expression is regulated by IL-1, IL-18 and type I IFN. 
Since TLR3/7 stimulation leads to the production of IFN, but not to IL-1/IL-18, we 
next investigated whether the co-expression between TLR3/7 and IL-1/IL-18 could 
be explained by IL-1/IL18-induced up regulation of these receptors. To this aim, we 
cultured monocytes (TLR7-expressing cells), monocyte-derived dendritic cells (TLR3-
expressing cells) and RA synovial fibroblasts (TLR3-expressing cells) in the presence 
of IFN, IL-1 and IL-18. IFN did significantly enhance the TLR3 mRNA expression 
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on RA synovial fibroblasts and monocyte-derived DC, and TLR7 mRNA expression 
on monocytes (Figure 1). This increase in TLR expression was equal between RA 
patients (n=5) and healthy volunteers (n=5) and was specific for TLR3 and TLR7, 
since the expression of TLR2 as well as TLR4 was not altered (data not shown). In 
contrast, IL-1 and IL-18 had no effect on the expression of TLR3/7 excluding a 
direct role in their co-expression with TLR3/7. 
 
IFN mediated up regulation of TLR3/7 is functional. 
As we demonstrated that expression of TLR3 and TLR7 was strongly up regulated by 
IFN, we sought evidence to whether this enhanced TLR expression was functional, 
in terms of increased TLR-mediated cytokine production. To this aim, we incubated 
TLR7-expressing monocytes and TLR3-expressing monocyte-derived DC and RA 
synovial fibroblasts (n=8) with IFN or medium and subsequently stimulated TLR3 or 
TLR7 with poly(IC) and loxoribine as appropriate. As anticipated, TLR7 stimulation on 
monocytes and TLR3 stimulation on monocyte-derived DC and RASF led to 
production of IL-6 and TNF, which was significantly enhanced when the cells were 
pre-incubated with IFN, compared to cells that were stimulated with TLR3/7 ligands 
alone (Figure 2). These data underline that the up regulation of TLR3/7 by type I IFN 
is functional. 
 
Type I IFN augments TLR4 mediated cytokine production providing the missing link 
explaining co-expression between TLR3/7 and IL-1/IL-18. 
Since TLR4 triggering is well recognized as a potent inducer of inflammatory 
mediators including IL-1 and IL-18, we postulated that stimulation of TLR3/7 leading 
to the production of type I IFN perhaps augments the TLR4 response ending up in 
the production of IL-1 and IL-18. To test this, we pre-stimulated monocyte-derived 
DC with IFN and next stimulated them with the TLR4 agonist lipopolysaccheride 
(LPS). Surprisingly, pre-stimulation with IFN resulted in a marked augmentation (4-
fold) of TLR4 mediated secretion of TNF by DC from healthy controls (3044 pg/ml 
vs. 800 pg/ml, P = 0.01, n=5) (Figure 3). In addition, pre-incubation with type I IFN 
augmented the TNF production by the combination of TLR3/4 ligands by almost 3-
fold (1880 pg/ml vs. 5010 pg/ml, P = < 0.01). Compared to DC from healthy controls, 
stimulation of DC from RA patients with TLR4 led to a clear augmented TNF 
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production as previously described (22). Notably, DC obtained from RA patients 
(n=4) produced a 4-fold higher level of TNF upon stimulation with IFN/LPS (12344 
pg/ml vs. 3044 pg/ml, P = 0.001) and IFN /LPS/Poly-IC (19876 pg/ml vs. 5003 
pg/ml), P = 0.01) compared to those DC from healthy individuals. Altogether these 
data implies an augmented TLR4 response that is orchestrated by pre-stimulation 
with type I IFN, which is even more pronounced in RA patients. 
 
 
 11
Discussion 
In this study we demonstrated that TLR3 and TLR7 in synovial tissue from RA 
patients was associated with the presence of IL-1, IL-18 and type I IFN. Since 
TLR3/7 mediated cell activation did not result in IL-1/IL-18 secretion and TLR3/7 
expression was not regulated by these mediators, we sought evidence for the 
underlying mechanism that explains the relationship between these mediators as 
observed in the synovium. Remarkably, we found that pre-incubation of DC with 
IFN led to clear augmentation of TLR4 mediated responses. In this light it is 
tempting to speculate that TLR3/TLR7 triggering leads to the production of type I IFN, 
which in turn augments TLR4 mediated triggering leading to the production of pro-
inflammatory mediators explaining the co-expression between TLR3/7 and IL-1/IL-
18. 
 
IFN type I is the key cytokine that regulates the innate immune response against 
viruses (21). Type I IFN is released upon transcription of IRF-3 or IRF-7, which can 
be induced following TLR3- or TLR7-mediated cell activation. TLR3 and TLR7 are 
highly expressed in synovial tissue from RA patients (22) and TLR3 and TLR7 
ligands, such as Cytomegalovirus, Epstein-Barr virus and Parvovirus B19 have been 
demonstrated in the synovial joints from RA patients also (1, 3, 23). The observation 
that a type I IFN signature is present in the synovium in a substantial part of RA 
patients support the notion that TLR3 and/or TLR7 triggering is likely to occur in RA 
synovium. In this light, it is tempting to speculate that exposure to TLR3/TLR7 
agonists might sensitize the synovial milieu for TLR4 ligands via IFN production 
acting as a key regulator in maintaining the inflammation processes during RA. For 
several reasons, IFN therapy has been expected to have beneficial effect in RA as 
comparable to that seen in multiple sclerosis (reviewed in (24)). IFN therapy was 
shown to be effective in animal models of collagen-induced arthritis (CIA). However, 
several clinical trials of IFN in patients with RA have been ineffective so far (25-27). 
The fact that IFN type I strongly up regulates TLR3/TLR7 expression and tunes TLR4 
responses, which in turn are continuously stimulated by ligands present in the 
synovial joints, might in fact maintain the inflammatory processes and therefore lead 
to IFN therapy failure.  
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Identification of endogenous TLR agonists is of great interest in terms of autoimmune 
disorders. In particular for TLR4 several endogenous agonist have been described 
thus far. For example hyaluronan fragments, heparan sulfate, fibronectin and (small) 
heat-shock proteins can all be released in RA joints as a result of inflammation-
induced tissue injury and cell stress (11-13, 28). In addition, For instance, Brentano 
et al. described an endogenous ligand for TLR3, as endogenous RNA, released from 
necrotic synovial fluid cells, was able to TLR3-mediated activation of RA synovial 
fibroblast (10). Highly conserved RNA sequences within small nuclear 
ribonucleoprotein particles are able to activate immune cells via TLR7 and could act 
as an endogenous auto antigen in systemic lupus erythematosus (29, 30). Thus, 
triggering of TLR3/7 pathways do not necessarily derive from viruses but might well 
originate from the host itself. TLR-mediated immune responses in the synovial joints 
might result in the release of endogenous TLR ligands, originating from cells under 
stress or tissue damage. Therefore is not unlikely that a self sustaining loop of TLR-
activation and generation of new endogenous TLR ligands might lead to a chronic 
inflammatory process as occurs during RA.  
 
Lately, it has been demonstrated that stimulation of several different TLR at the same 
time, leads to synergistically induced levels of pro-inflammatory mediators (22, 31). 
Our data indicates that cytokine levels induced in a synergistic fashion by co-
stimulation of TLR3 and TLR4 were even more enhanced when cells were pre-
incubated with type I IFN. The exact mechanisms underpinning the augmented TLR4 
response after pre-incubation with type I IFN is not yet understood. From our data we 
can conclude that this phenomenon is not explained by an increased expression of 
TLR4 itself since pre-incubation with type I IFN did not alter its mRNA expression. 
Perhaps the explanation for this lies within an up regulation of adaptor molecules or 
down regulation of intracellular inhibitors that are part of the TLR4 pathways 
(reviewed in (32)).  Since the augmentation of TLR4 responses by type I IFN was 
significantly more potent in RA patients, further investigation into the causative 
pathways is highly desirable because it might open novel insights to battle this 
condition selectively. 
 
Altogether, in this study we showed that the expression of TLR3 and TLR7 was co-
expressed with IFN, IL-1 and IL-18 in RA synovial tissue. Furthermore, we 
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demonstrated the involvement of IFN in the regulation of TLR3/TLR7 expression 
and function but also to an augmented TLR4 mediated response. These 
observations might, at least partly, explain the role for type I IFN in the inflammatory 
cascade of RA.  
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Table 1: Oligonucleotide primers for quantitative PCR analysis 
cDNA Forward primer Reverse primer 
hGAPDH ATC TTC TTT TGC GTC GCC AG TTC CCC ATG GTG TCT GAG C 
hTLR3 
AGA GTT GTC ATC GAA TCA AAT 
TAA AGA G 
CAT TGT TCA GAA AGA GGC 
CAA AT 
hTLR7 
TGC CAT CAA GAA AGT TGA TGC 
T 
GGA ATG TAG AGG TCT GGT 
TGA AGA G 
hIL-1 AAT CTG TAC CTG TCC TGC GTG 
TT 
TGG GTA ATT TTT GGG ATC 
TAC ACT CT 
 
Software package Primer Express Version 2.0 (Applied Biosystems) was used to 
identify appropriate primer sets. All sequences are presented in the 5’3’direction. 
 
 
 
 
 
 
 16
  
Table 2. Co-expression of TRL3/7 with Type I IFN, IL-1 and IL-18 in 
RA synovium. 
  Correlation (r) P-value 
Co-expression TLR – Type I IFN 
TLR3 – Type I IFN   
 Lining 0.76 0.02 
 Sub-lining 0.77 0.01 
TLR7 – Type I IFN   
 Lining 0.70 0.04 
 Sub-lining 0.84 0.01 
Co-expression TLR – Interleukin 1 
TLR3 – IL-1   
 Lining 0.54 0.02 
 Sub-lining 0.22 NS 
TLR7 – IL-1   
 Lining 0.32 NS 
 Sub-lining 0.17 NS 
Co-expression TLR – Interleukin 18 
TLR3 – IL-18   
 Lining 0.48 0.04 
 Sub-lining 0.11 NS 
TLR7 – IL-18   
 Lining 0.48 0.04 
 Sub-lining 0.16 NS 
NS; not significant 
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Legends to the figures 
 
 
Figure 1: Effects of type I IFN, IL-1 and IL-18 on TLR3/7 expression. 
 IL-1, IL-18 and IFN induced TLR3/7 mRNA expression by monocytes (A), 
monocytes-derived DC (B) and RA synovial fibroblasts (C) from RA patients (n=5) 
and healthy controls (n=5). Cells were incubated with 20ng IL-1, IL-18 and 100 
IU/ml IFN for 8 hours and subsequently TLR mRNA expression was determined by 
real-time PCR. Graphs represent the mean  SD. 
 
Figure 2: Functionality of increased TLR3/7 expression by type I IFN. 
Monocytes (panel A), monocyte-derived DC (panel B) and RA synovial fibroblasts 
(panel C) from RA patients (n=5) were stimulated with TLR3/7 specific ligands after 
they were incubated with medium only (grey bars) or medium containing IFN (100 
U/ml) (black bars) for 10 hrs. Graphs represent the mean  SD. 
 
Figure 3. Pre-incubation with type I IFN augments TLR4 responses. 
TNF secretion by monocyte-derived DC co-incubated with (24 hrs) agonists for 
TLR3 (TLR3), TLR4 (purified LPS) or the combination of both. TNF secretion was 
compared between DC that were pre-stimulated with 100 U/ml IFN for 10 hrs and 
those who were not. DC from healthy individuals (n=5) and RA patients (n=4) were 
compared. Graphs represent the mean  SD. * Represents a P-value lower then 
0.05. 
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